Oyster Point Pharma Inc logo

OYST - Oyster Point Pharma Inc News Story

$21.19 0.2  0.9%

Last Trade - 14/04/21

Sector
Healthcare
Size
Mid Cap
Market Cap £395.8m
Enterprise Value £255.7m
Revenue £n/a
Position in Universe 3426th / 6848

Oyster Point Pharma to Participate in the 41st Annual Cowen Healthcare Conference

Thu 25th February, 2021 9:01pm
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210225:nGNX7wrcbr&default-theme=true


PRINCETON, N.J., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc.
(Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the
discovery, development and commercialization of first-in-class pharmaceutical
therapies to treat ocular surface diseases, today announced that the Company
will participate virtually in the 41(st) Annual Cowen Healthcare Conference on
Tuesday, March 2, 2021, at 11:10 a.m. ET, and host investor meetings.

To access the live webcast, please visit the “Investors and News” section
of the Oyster Point Pharma website at https://investors.oysterpointrx.com/.

About Oyster Point Pharma, Inc.

Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on
the discovery, development, and commercialization of first-in-class
pharmaceutical therapies to treat ocular surface diseases. Oyster Point
Pharma’s lead product candidate, OC-01 (varenicline) nasal spray, a highly
selective cholinergic agonist, is being developed as a nasal spray to treat
the signs and symptoms of dry eye disease. In pre-clinical and clinical
studies, OC-01 (varenicline) nasal spray was shown to have a novel mechanism
of action via activation of the trigeminal parasympathetic pathway to
stimulate the glands and cells responsible for natural tear film production,
known as the lacrimal functional unit. OC-01 (varenicline) nasal spray is an
investigational new drug and has not been approved for any use in any country.
The safety and efficacy of OC-01 (varenicline) nasal spray have not previously
been established.

Investor Contact: 
Tim McCarthy 
LifeSci Advisors, LLC 
(212) 915-2564 
investors@oysterpointrx.com

Media Contact: 
Sheryl Seapy
W2O Group 
(213) 262-9390 
sseapy@w2ogroup.com 

(https://www.globenewswire.com/NewsRoom/AttachmentNg/4fced6c3-e6da-4081-8986-0dd0667a8d7f)



GlobeNewswire, Inc. 2021
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.